ArticleCancers2022

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers.

Elena Shklovskaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.